887 resultados para maladie de Parkinson
Resumo:
Estudos prévios indicam que o extrato de folhas de mogno Swietenia macrophylla possui composição química rica em substâncias antioxidantes com efeito neuroprotetor em cultura. Um dos principais mecanismos envolvidos na neurodegeração da Doença de Parkinson (DP) é o estresse oxidativo. Portanto, substâncias antioxidantes são candidatas potenciais para terapias que retardem o processo neurodegenerativo da doença. Este estudo tem por objetivo caracterizar os efeitos do extrato de folhas de mogno frente à degeneração nigroestriatal e alterações comportamentais de camundongos expostos a uma única injeção intraestriatal de 6-OHDA unilateralmente. Foram utilizados camundongos machos, os quais foram submetidos à cirurgia estereotáxica para a injeção de 20 μg de 6-OHDA no estriado esquerdo. Os animais foram subdivididos em 4 grupos, de acordo com a dose de extrato de mogno administrada. O extrato foi aplicado por via intraperitoneal nos 7 primeiros dias após a injeção de 6-OHDA nas doses de 0,0 (controle), 0,5 (G1), 1,0 (G2) e 5,0 mg/kg (G3). O grupo controle (GC) recebeu injeções de salina a 0,9% (veículo). Foi feita análise da ambulação no campo aberto antes, no 7º e no 21º dias e do número de rotações induzidas por apomorfina no 7º e no 21º dias após a cirurgia. Avaliação da neurodegeneração foi realizada através da contagem de neurônios dopaminérgicos TH+ na substância negra por estereologia. Como resultado, encontrou-se diferença estatisticamente significativa no 21º dia, onde os grupos G2 e G3 apresentaram redução no comportamento ambulatório em relação aos grupos G1 e GC; este dois últimos tiveram comportamento ambulatório equivalente entre si. Em relação às rotações induzidas por apomorfina, no 21º dia, o G1 apresentou média de rotações significativamente menor do que os grupos GC, G2 e G3. Na contagem de células, G1 apresentou diminuição na perda dos neurônios dopaminérgicos estatisticamente significativa em relação ao controle. Assim, concluímos que o extrato de mogno na concentração de 0,5 mg/kg promoveu neuroproteção na neurodegeneração do sistema nigroestriatal induzida por 6-OHDA.
Resumo:
Pós-graduação em Ciências Farmacêuticas - FCFAR
Resumo:
A doença de Parkinson (DP) é a segunda doença neurodegenerativa mais comum em idosos, caracterizada pela neurodegeneração de neurônios dopaminérgicos da substância negra (SN), com etiologia não claramente estabelecida, entretanto as causas podem estar associadas a exposição de toxinas ambientais e fatores genéticos. Os processos patológicos envolvidos na DP são disfunção mitocondrial, estresse oxidativo, inflamação e excitotoxicidade. A sintomatologia da DP são alterações motoras, cognitivas e autonômicas. Contudo, poucos estudos analisam os sintomas não-motores da DP, principalmente em modelos animais. Nesse contexto o objetivo deste trabalho foi avaliar sintomas não-motores da DP em modelo animal com lesão provocada pela neurotoxina 6-hidroxidopamina com duas doses diferentes, injetadas bilateralmente no estriado. Para alcançar nossos objetivos realizamos os testes de campo aberto, apomorfina, labirinto aquático de Morris e testes de discriminação olfativa, além de análises histológicas. Nossos resultados mostraram alterações motoras, déficits de memória e aprendizado, associadas a diminuição de células dopaminérgicas na SN, neurônios estriatais e neurônios da região hipocampal CA1. Dessa forma, esse modelo para os sintomas não-motores da DP pode ser utilizado para a compreensão dos mecanismos que envolvem a doença, assim como para avaliar medidas terapêuticas que possam retardar ou interromper a progressão da DP.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
This study aimed to evaluate the effect of muscle strengthening in the balance, mobility and quality of life (QoL) in individuals with Parkinson's disease (PD), and to check the correlation between muscle strengthening and QoL. Nine subjects belonging to both sexes, diagnosed with PD, participated in this study. Initially, they went through an evaluation of their balance and functional mobility through the Berg Balance Scale (BBS), the Timed Up and Go (TUG) test, and a QoL test through the Parkinson's Disease Questionnaire (PDQ-39). The subjects also performed a test for determining the maximum load (one-repetition maximum) for the muscle groups trained. After the normality and homogeneity of the data were verified, the Student's t-test and Spearman correlation test were carried out. A significance level of p<0.05 was considered. We verified an improvement in balance (p=0.008) and QoL (p=0.013), and a negative correlation between balance and QoL (evaluation: r=-0.65 and p=0.05, revaluation: r=-0.82 and p=0.005). It was concluded that muscle strengthening was efficient in the improvement of balance and QoL in individuals with PD.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
The purpose of this study was to analyze the effect of different exercise programs on the psychological and cognitive functions in patients with Parkinson's disease (PD). Forty-five patients with PD participated in the study. The participants were randomized in three intervention programs: Group-1 (n=15, cognitive-activities), Group-2 (n=15, multimodal exercise) and Group-3 (n=15, exercises for posture and gait). The clinical, psychological and cognitive functions were assessed before and after 4 months of intervention. Univariate analysis did not reveal significant interactions between groups and time (p>0.05). However, univariate analysis for time revealed differences in stress level and memory. Participants showed less physical stress (p<0.01) and overall stress (p < 0.04) and higher performance in episodic declarative memory (p < 0.001) after exercise. These findings suggest that group work with motor or non-motor activities can improve cognitive and psychological functions of patients with PD.
Resumo:
The severity of Parkinson's disease (PD) and PD's motor subtypes influence the components of physical capacity. The aim of this study was to investigate the impact of both PD severity and motor subtype in the performance of these components. Thirty-six PD patients were assigned into four groups: Tremor (TD) initial and TD mild, akinetic-rigid (AR) initial, and AR mild. Patients' strength, balance, coordination, mobility and aerobic capacity were evaluated and groups were compared using a two-way ANOVA (severity and subtype as factors). AR presents a poorer performance than TD in almost all tests. Also this performance was worsened with the advance of the disease in AR, contrary to TD. We conclude that AR and TD subgroups are different about their performance on physical capacity components, moreover, this performance worsens with the advance of the disease of the AR group, but not for TD.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Although the exact cause of neuronal loss in Parkinson's disease is not known, evidence points to oxidative stress and the production of reactive oxygen species as the main events that occur in the substantia nigra pars compacta of the brain of parkinsonians. EGb761 is an extract of the leaves from the Ginkgo biloba tree that has been reported as an antioxidant and neuroprotective agent. The objective of this work was to perform a systematic review of the studies that analysed the effect of Ginkgo biloba extract on Parkinson's disease or Parkinsonism. This research was conducted using the following databases: Medline, PsycInfo, Cinahl, Sigle, Lilacs, Scielo, Cochrane Library, and Embase. Initially, we selected 32 articles. After a more detailed analysis, only 10 articles remained. One of the hypotheses for the positive effect of EGb761 on Parkinson's disease is the reduction or inhibition of monoamine-oxidase activity. This enzyme metabolises dopamine, inducing the formation of free radicals, which in turn damage nigrostriatal neurons. Another hypothesis is that the neuroprotective effect of EGb761 against 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and MPP+ toxins. As there are few studies on the effect of EGb761 on humans, this review could contribute new data to further the discussion of this issue.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Introduction: Parkinson’s disease (PD) is a chronic disease of the nervous system, characterized by degeneration of neurons in the mesencephalic substantia nigra, leading to a clinical state of rest tremor, bradykinesia, muscular rigidity and postural instability. Physical therapy seeks to act by slowing the progression of the disease and when done in a group and maintain and / or improving the motor skills of the individual, can provide psychosocial benefi ts. Objective: examine the infl uence of the physical therapy group in balance, functional mobility and quality of life of individuals with PD. Method: participated in this study 04 subjects were female, mean age 67.75 (± 9.5) years, with medical diagnosis of PD, stages 1 to 3 of the Hoehn & Yahr. Before starting treatment, subjects underwent an assessment of the balance (BBS), functional mobility (TUG) and the quality of life (PDQ-39).The treatment was performed in groups, for a period of 10 weeks, lasting 60 minutes each session twice a week, totaling 20 sessions of physiotherapy. Upon completion of the treatment period the subjects were again assessed for balance, functional mobility and quality of life. The data were analyzed using the Student t-test, with signifi cance level of 5% (p ≤ 0.05). Results: statistical analysis showed signifi cant differences in three variables: equilibrium (p = 0.010), functional mobility (p = 0.029) and quality of life (p = 0.004), after physiotherapy intervention. Conclusion: physiotherapy treatment was group provides better balance, functional mobility and quality of life of patients with PD.